Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

New approaches of B-cell-directed therapy: beyond rituximab

(2009) Thomas Dörner et al.   CURRENT OPINION IN RHEUMATOLOGY

Preclinical Support for Combination Therapy in the Treatment of Autoimmunity with Atacicept

(2009) Rafael Ponce   TOXICOLOGIC PATHOLOGY

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

(2008) E Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

(2008) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases

(2008) Changhai Ding   EXPERT OPINION ON BIOLOGICAL THERAPY

Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis

(2008) Ivan Nestorov et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept

(2008) Michela Carbonatto et al.   TOXICOLOGICAL SCIENCES

B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor   antagonists: differential effects between good and poor clinical responders

(2007) D T La et al.   ANNALS OF THE RHEUMATIC DISEASES